-
BUDGET IMPACT OF INTRODUCING TAPINAROF, A NEW ARYL HYDROCARBON RECEPTOR AGONIST, FOR THE TREATMENT OF ATOPIC DERMATITIS IN ADULT AND PEDIATRIC PATIENTS, FROM A U.S. MEDICAID PLAN PERSPECTIVE
Mar 18, 2026, 21:38 PM -
REPRESENTATIVENESS OF LINKED CLAIMS-EHR DATA: CLAIMS-ONLY VS CLAIMS+EHR POPULATIONS
Mar 18, 2026, 21:38 PM -
CROSS-VALIDATION OF AN EARLY COST-EFFECTIVENESS MODEL FOR SPECTRIS™ THERAPY USING THE ALZHEIMER’S DISEASE OPEN-SOURCE IPECAD MODEL FRAMEWORK
Mar 18, 2026, 21:38 PM -
FROM SINGLE-ARM EVIDENCE TO HTA-READY SURVIVAL COMPARISONS: EXTENDING MULTILEVEL NETWORK META-REGRESSION TO DISCONNECTED NETWORKS FOR TIME-TO-EVENT OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA
Mar 18, 2026, 21:38 PM -
CHARACTER STRENGTHS AND BURNOUT DIMENSIONS AMONG EMERGENCY CARE PROFESSIONALS IN HUNGARY: A CROSS-SECTIONAL STUDY
Mar 18, 2026, 21:38 PM -
FIRST-LINE SYSTEMIC TREATMENT PATTERNS IN METASTATIC UROTHELIAL CARCINOMA IN US COMMUNITY ONCOLOGY PRACTICES
Mar 18, 2026, 21:38 PM -
MACHINE LEARNING-BASED PREDICTION FOR NEPHROTOXICITY IN ONCOLOGY PATIENTS WITH CHEMOTHERAPY
Mar 18, 2026, 21:38 PM -
EMPLOYEE PERCEPTIONS AND EXPERIENCES WITH TIRZEPATIDE TREATMENT FOR OBESITY OR OVERWEIGHT IN THE US
Mar 18, 2026, 21:38 PM -
MODELING THE IMPACT OF SOTATERCEPT ON MORBIDITY AND MORTALITY IN PULMONARY ARTERIAL HYPERTENSION: A MEXICAN POPULATION HEALTH PERSPECTIVE
Mar 18, 2026, 21:38 PM -
HEALTH ECONOMICS PUBLISHED EVIDENCE FOR FDA-APPROVED DRUGS (2022-2023): AVAILABILITY, TIMING & DISSEMINATION PATHWAY
Mar 18, 2026, 21:38 PM -
SPENDING ON GENE THERAPIES FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Mar 18, 2026, 21:38 PM -
PATIENT-CENTRIC PATHWAYS: SURVEYING TREATMENT ACCESS AND SUPPORT FOR RARE DISEASES, INCLUDING RARE CANCERS, IN EUROPE
Mar 18, 2026, 21:38 PM -
WHY CURRENT INTERTEMPORAL DISCOUNTING METHODS ARE WRONG, HOW THEY DISTORT HEALTH TECHNOLOGY ASSESSMENT, COST-EFFECTIVENESS ANALYSIS AND ESTIMATES OF THE VALUE OF A LIFE-YEAR AT FULL HEALTH, AND HOW TO FIX THE PROBLEM
Mar 18, 2026, 21:38 PM -
THE BLOCKBUSTER BATTLE IN OBESITY: DO NEWER SEMAGLUTIDE DOSES CLOSE THE GAP? A TIME-COURSE MODEL-BASED NMA
Mar 18, 2026, 21:38 PM -
COMPARISON OF BENEFIT DESIGN FOR DIABETES MEDICATIONS BETWEEN CONVENTIONAL MEDICARE ADVANTAGE PLANS AND CHRONIC CONDITION SPECIAL NEEDS PLANS
Mar 18, 2026, 21:38 PM -
COMPARATIVE RISK OF SUICIDAL IDEATION AND SELF-HARM AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH BREXPIPRAZOLE VERSUS OTHER ORAL ATYPICAL ANTIPSYCHOTICS: A PROPENSITY SCORE-MATCHED COHORT ANALYSIS
Mar 18, 2026, 21:38 PM -
ASSESSING ACCESS TO INNOVATIVE ORPHAN MEDICINES IN LATIN AMERICA: A CROSS-COUNTRY VALUE AND ACCESS ANALYSIS
Mar 18, 2026, 21:38 PM -
THE DYNAMICS OF EXACERBATION-RELATED HEALTH-STATE TRANSITIONS IN UNCONTROLLED ASTHMA: A MARKOV-BASED MULTI-CRITERIA ANALYSIS
Mar 18, 2026, 21:38 PM -
COST-BENEFIT ANALYSIS OF CLOSED-SYSTEM AND OPEN-SYSTEM INFUSION OF HUMAN SERUM ALBUMIN IN ICU PATIENTS
Mar 18, 2026, 21:38 PM -
TRENDS IN INPATIENT COSTS AND DRIVERS OF HIGH-COST HOSPITALIZATIONS AMONG INDIVIDUALS WITH OPIOID USE DISORDER
Mar 18, 2026, 21:38 PM
